Back to School: How biopharma can reboot drug development. Access exclusive analysis here

YMB completes Phase II cancer enrollment

YM BioSciences (LSE:YMB; TSE:YM.PR.B) completed enrollment in a North American Phase

Read the full 112 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE